Article
- The EMBO Journal (2003) 22, 469 - 478
- doi:10.1093/emboj/cdg051
Subject Category:
PDE5 is converted to an activated state upon cGMP binding to the GAF A domain
Sergei D. Rybalkin1, Irina G. Rybalkina1, Masami Shimizu-Albergine1, Xiao-Bo Tang1 and Joseph A. Beavo1
- Department of Pharmacology, University of Washington, Seattle, WA 98195-7280, USA
Correspondence to:
Joseph A. Beavo, E-mail: beavo@u.washington.edu
Received 2 September 2002; Accepted 3 December 2002; Revised 2 December 2002
Abstract
cGMP-specific, cGMP-binding phosphodiesterase (PDE5) regulates such physiological processes as smooth muscle relaxation and neuronal survival. PDE5 contains two N-terminal domains (GAF A and GAF B), but the functional roles of these domains have not been determined. Here we show that recombinant PDE5 is activated directly upon cGMP binding to the GAF A domain, and this effect does not require PDE5 phosphorylation. PDE5 exhibited time- and concentration-dependent reversible activation in response to cGMP, with the highest activation (9- to 11-fold) observed at low substrate concentrations (0.1
M cGMP). A monoclonal antibody directed against GAF A blocked cGMP binding, prevented PDE5 activation and decreased basal activity, revealing that PDE5 in its non-activated state has low intrinsic catalytic activity. Activated PDE5 showed higher sensitivity towards sildenafil than non-activated PDE5. The stimulatory effect of cGMP binding on the catalytic activity of PDE5 suggests that this mechanism of enzyme activation may be common among other GAF domain-containing proteins. The data also suggest that development of agonists and antagonists of PDE5 activity based on binding to this site might be possible.
Keywords:
- cyclic GMP,
- GAF domain,
- PDE5,
- sildenafil,
- smooth muscle



